Pharmaceutical

Janssen’s BALVERSA receives EC approval for metastatic urothelial carcinoma

The European Commission (EC) has approved Janssen's BALVERSA as a treatment for adults with unresectable or metastatic urothelial carcinoma.

Aug 27, 2024 - 04:00
Janssen’s BALVERSA receives EC approval for metastatic urothelial carcinoma
The European Commission (EC) has approved Janssen's BALVERSA as a treatment for adults with unresectable or metastatic urothelial carcinoma.
Read the original article

Tags:

Previous Article

China NMPA grants approval for GenFleet’s fulzerasib to treat lung cancer

Next Article

Germany to Provide 100,000 Mpox Vaccine Doses to Combat Outbreak in Africa

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Forbion European Acquisition and enGene sign merger deal

Forbion European Acquisition and enGene sign merger deal

May 18, 2023

STAT+: General Catalyst wants to take over a safety-net health system in Akron. The city has questions

STAT+: General Catalyst wants to take over a safety-net...

Feb 1, 2024

STAT+: After sickle-cell screwups, Bluebird Bio’s only option might be a company sale

STAT+: After sickle-cell screwups, Bluebird Bio’s only ...

Dec 11, 2023